ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD

ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD

ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD 150 150 Eyevensys

Eyevensys presents data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).

Read More
Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference   
Eyevensys Announces Positive Preclinical Data Demonstrating Superiority of EYS809 over Aflibercept for Wet Age-Related Macular Degeneration (AMD) at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Start Typing